{
    "clinical_study": {
        "@rank": "109107", 
        "arm_group": {
            "arm_group_label": "NEOD001", 
            "arm_group_type": "Experimental", 
            "description": "NEOD001 will be administered intravenously once every 28 days.  The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001.  Approximately 20 additional subjects will be treated with the maximum tolerated dose."
        }, 
        "brief_summary": {
            "textblock": "Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30\n      subjects with AL amyloidosis.  Expansion phase to evaluate safety, efficacy and\n      pharmacokinetics of NEOD001 in 20 additional subjects at the maximum tolerated dose."
        }, 
        "brief_title": "Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Amyloidosis", 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "detailed_description": {
            "textblock": "The purpose of the dose escalation phase of the study is to determine the maximum tolerated\n      dose/Phase 2 recommended dose of NEOD001 when given as a single agent intravenously in\n      approximately 30 subjects with AL amyloidosis.\n\n      The purpose of the expansion phase of the study is to evaluate the safety, preliminary\n      efficacy and pharmacokinetics of single agent NEOD001 at the maximum tolerated dose/Phase 2\n      recommended dose in approximately 20 additional evaluable subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females aged \u226518 years;\n\n          2. ECOG performance status (PS) 0-2;\n\n          3. Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not\n             eligible);\n\n          4. Received at least one prior systemic therapy, which may include stem cell transplant,\n             for AL amyloidosis;\n\n          5. Have adequate organ function;\n\n          6. Ability to understand and willingness to sign informed consent prior to initiation of\n             any study procedures.\n\n        Exclusion Criteria:\n\n          1. Secondary or familial amyloidosis;\n\n          2. Life expectancy of < 3 months;\n\n          3. Symptomatic multiple myeloma;\n\n          4. Hypersensitivities to other monoclonal antibodies;\n\n          5. Known HIV infection;\n\n          6. Women who are lactating;\n\n          7. Any other condition or prior therapy, which in the opinion of the PI, would make the\n             subject unsuitable for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707264", 
            "org_study_id": "NEOD001-001"
        }, 
        "intervention": {
            "arm_group_label": "NEOD001", 
            "description": "Monoclonal antibody administered by intravenous infusion every 28 days.", 
            "intervention_name": "NEOD001", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AL amyloidosis", 
            "Primary amyloidosis"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Michaela Liedtke, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jjensen@tuftsmedicalcenter.org", 
                    "last_name": "Jodi Jensen, RN", 
                    "phone": "617-636-5558"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Tufts Medical Center"
                }, 
                "investigator": {
                    "last_name": "Raymond Comenzo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anthony.shelton@bmc.org", 
                    "last_name": "Anthony Shelton", 
                    "phone": "617-638-5612"
                }, 
                "contact_backup": {
                    "email": "stephen.lo@bmc.org", 
                    "last_name": "Stephen Lo", 
                    "phone": "617-638-8274"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Boston University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "David C Seldin, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "houdec@karmanos.org", 
                    "last_name": "Christiane Houde, BS, CCRP", 
                    "phone": "313-576-9381"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jeffrey A Zonder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ann Birgin, CRA", 
                    "phone": "507-284-8828"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Morris A Gertz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Landauh@mskcc.org", 
                    "last_name": "Heather Landau, MD", 
                    "phone": "212-639-8808"
                }, 
                "contact_backup": {
                    "last_name": "Hani Hassoun, MD", 
                    "phone": "(212) 639-3228"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Heather Landau, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "scott.weber@uphs.upenn.edu", 
                    "last_name": "Scott Weber, BA", 
                    "phone": "215-349-8913"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Hospital of the University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Brendan Weiss, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis", 
        "other_outcome": [
            {
                "description": "\u2022 Hematologic response", 
                "measure": "Hematologic Response", 
                "safety_issue": "Yes", 
                "time_frame": "28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator"
            }, 
            {
                "description": "Organ response\nChanges in organ function markers", 
                "measure": "Organ response", 
                "safety_issue": "Yes", 
                "time_frame": "28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator"
            }
        ], 
        "overall_contact": {
            "email": "theresa.neumann@prothena.com", 
            "last_name": "Theresa Neumann, PhD"
        }, 
        "overall_official": {
            "affiliation": "Onclave Therapeutics Ltd", 
            "last_name": "Theresa Neumann, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse event profile\nDose limiting toxicity and maximum tolerated dose", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator"
            }, 
            {
                "description": "Adverse event profile\nDose Limiting Toxicity and maximum tolerated dose", 
                "measure": "Maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022 Pharmacokinetic parameters including Cmax, Tmax, AUC, Cav, Cmin, t\u00bd, CL, and Vz", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator"
            }, 
            {
                "description": "\u2022 Measurement of anti-NEOD001 antibodies", 
                "measure": "Immunogenicity", 
                "safety_issue": "Yes", 
                "time_frame": "28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator"
            }
        ], 
        "source": "Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}